# Retatrutide vs Tirzepatide: Triple vs Dual Agonist for Weight Loss **By TelosRX Editorial Team** · 2026-08-01 **[Retatrutide vs tirzepatide](https://www.telosrx.com): both target GLP-1 receptors for weight loss, but one adds a third mechanism — glucagon activation — that drove Phase 3 weight loss to 28.3% at 80 weeks, compared to tirzepatide's 22.5%. Here's what that difference means in practice.** Tirzepatide is the current standard. It's FDA-approved, broadly available, and consistently delivers meaningful weight loss for people with obesity. Retatrutide is what's coming — a triple agonist that, in Eli Lilly's TRIUMPH-1 Phase 3 trial, delivered higher peak weight loss than any previously approved obesity drug. If you're weighing your options or planning ahead, this comparison gives you the clinical facts. ## How the Mechanisms Differ The difference starts at the receptor level. Tirzepatide is a dual agonist: it activates GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide) receptors. GLP-1 slows gastric emptying and signals satiety to the brain. GIP enhances insulin release and appears to amplify GLP-1's appetite-suppressing effects. Retatrutide adds a third receptor: glucagon. Glucagon signals the liver to release stored fat for energy and increases thermogenesis — your body's heat production and calorie burn at rest. That metabolic layer is where retatrutide's additional weight-loss advantage appears to originate. ## Retatrutide vs Tirzepatide: Head-to-Head Comparison Feature Tirzepatide Retatrutide Receptor targets GLP-1 + GIP (dual agonist) GLP-1 + GIP + glucagon (triple agonist) Peak trial weight loss ~22.5% at 72 weeks (SURMOUNT-1, 15 mg) ~28.3% at 80 weeks (TRIUMPH-1, 12 mg); 30.3% at 104 weeks Starting dose 2.5 mg/week subcutaneous 1 mg/week subcutaneous Maximum dose 15 mg/week 12 mg/week (Phase 3 dose) Escalation timeline 4–6 months to maintenance ~16 weeks to 12 mg FDA approval status Approved (Zepbound for obesity; Mounjaro for T2D) Not FDA-approved — investigational; Phase 3 complete Common side effects Nausea, constipation, diarrhea, vomiting Nausea 42%, diarrhea 32%, vomiting 25% at 12 mg (TRIUMPH-1) Noteworthy safety signal Gastroparesis risk at high doses (rare) Dysesthesia signal at 12 mg (Phase 2); heart rate increase Compounding availability Available via telehealth, subject to medical approval Not yet compoundable — FDA approval pending ## Phase 3 Clinical Trial Data: What We Know Now **Tirzepatide (SURMOUNT-1):** In the pivotal Phase 3 trial, tirzepatide at 15 mg produced an average 22.5% body weight reduction over 72 weeks in adults with obesity or overweight without diabetes. This was the strongest Phase 3 efficacy data for any approved GLP-1 class agent at its 2023 approval. See the full data in [The New England Journal of Medicine](https://www.nejm.org/doi/full/10.1056/NEJMoa2206038). **Retatrutide (TRIUMPH-1):** Eli Lilly's pivotal Phase 3 trial enrolled 2,339 adults without diabetes. At 80 weeks, the 12 mg dose group achieved an average 28.3% body weight reduction vs. 3.9% on placebo. An extended 104-week cohort reached 30.3% average weight loss in a higher-BMI subgroup. TRIUMPH-2 and TRIUMPH-3 reported positive topline results in July 2026. Full trial registrations are listed at [ClinicalTrials.gov](https://clinicaltrials.gov). That's roughly a 6-point difference in average percentage weight loss between the drugs' best Phase 3 results. On a 250-pound starting weight, that's the difference between losing approximately 56 pounds and 71 pounds over a similar timeframe. ## Side Effects: Overlapping Profiles, One Notable Signal Both drugs share the same dominant side effect class: GI symptoms that peak during dose escalation and typically diminish at maintenance. In TRIUMPH-1 at the 12 mg dose, nausea affected 42.4% of participants, diarrhea 32.0%, constipation 26.1%, and vomiting 25.3%. Tirzepatide's GI profile is similar in kind; rates vary by dose and titration speed. Retatrutide's Phase 2 data noted a dysesthesia signal (abnormal skin sensation) at the 12 mg dose in a subset of participants. This wasn't observed in tirzepatide trials. Phase 3 data will clarify its scope. A more pronounced resting heart rate increase was also observed with retatrutide compared to tirzepatide — a signal to monitor, particularly in patients with pre-existing cardiovascular conditions. ## Dosage and Escalation: Why Retatrutide Starts Lower Tirzepatide escalates in 2.5 mg increments every 4 weeks, starting at 2.5 mg and typically targeting 10–15 mg at maintenance. Most people report meaningful appetite suppression in the 5–7.5 mg range. Retatrutide starts at 1 mg weekly — lower than tirzepatide's starting dose — reflecting the more complex triple-mechanism. Full escalation to 12 mg takes approximately 16 weeks. Slower titration gives the glucagon-GLP-1-GIP combination time to be tolerated before reaching therapeutic doses. For options available today, [TelosRX](https://www.telosrx.com) offers asynchronous telehealth evaluation for compounded tirzepatide, subject to medical approval by a licensed provider. ## Regulatory Status: The Practical Decision Point Tirzepatide is FDA-approved as Zepbound (obesity) and Mounjaro (type 2 diabetes). Compounded tirzepatide has been available through licensed telehealth pharmacies during shortage periods, subject to medical evaluation — it is the accessible, evidence-backed option available today. Retatrutide is not FDA-approved. Phase 3 trials are complete with positive results. Eli Lilly is expected to file for FDA approval in 2026; a realistic approval window is 2027. Compounded retatrutide is not legally available through any licensed pharmacy — any source claiming to offer it is not operating within regulated pharmaceutical channels. ## Which to Consider: A Practical Framework - **You need something now:** Tirzepatide. FDA-approved, broadly studied, available through asynchronous telehealth evaluation subject to medical approval. - **You've plateaued on tirzepatide:** Retatrutide is the most likely next-option candidate — watch its FDA approval timeline. - **You have significant fatty liver disease:** Glucagon receptor activation may provide additive liver-fat reduction beyond weight loss; Phase 2 retatrutide data showed this signal. - **You're planning ahead:** Any future transition from tirzepatide to retatrutide would require a provider-issued prescription and individualized protocol — not a self-directed switch. Read our [full retatrutide overview](https://www.telosrx.com/blogs/glp1/retatrutide-weight-loss-triple-agonist-glp1) and [tirzepatide benefits guide](https://www.telosrx.com/blogs/glp1/tirzepatide-benefits) for individual deep-dives. ## Frequently Asked Questions ### Is retatrutide more effective than tirzepatide for weight loss? Phase 3 data from TRIUMPH-1 shows retatrutide at 12 mg produced about 28.3% average body weight reduction at 80 weeks, compared to tirzepatide's 22.5% at 72 weeks in SURMOUNT-1. These are separate trials with different populations — not a head-to-head study. Retatrutide is not FDA-approved; individual results vary and are subject to provider evaluation. ### How does retatrutide's glucagon mechanism add to weight loss? Glucagon signals the liver to release stored fat for fuel and increases thermogenesis — your body burns more calories at rest. GLP-1 and GIP primarily reduce appetite and improve insulin signaling; glucagon adds an energy expenditure component. This three-pathway approach appears to drive retatrutide's incremental weight-loss advantage, though real-world magnitude in diverse populations will become clearer post-approval. ### When will retatrutide receive FDA approval? Phase 3 TRIUMPH trials completed with positive topline results in 2026. Eli Lilly has indicated plans to file for FDA approval in 2026. FDA review typically takes 6–12 months, placing a realistic approval window in 2027. Timelines can shift based on the review process and any additional data requests from the FDA. ### Can I switch from tirzepatide to retatrutide when it's approved? Not today — retatrutide has no FDA approval. When approved, any transition would require evaluation by a licensed provider to determine appropriate starting dose, tolerability, and transition protocol. It is not a self-directed switch. Any compounded version would also require a provider-issued prescription. ### Are retatrutide's side effects worse than tirzepatide's? Both drugs have similar GI side effect profiles. Retatrutide's TRIUMPH-1 data showed nausea in 42% of participants at 12 mg — comparable in kind to tirzepatide at high doses. The Phase 2-era dysesthesia signal and more pronounced heart rate increase are specific to retatrutide and warrant monitoring through Phase 3 follow-up data as it is published. ### Is compounded retatrutide available through telehealth pharmacies? No. Compounded retatrutide is not legally available through any licensed pharmacy in the United States. Retatrutide is an investigational drug with no FDA approval. Compounding a non-approved drug's active ingredient falls outside regulated pharmaceutical practice. Do not purchase from unverified or unregulated sources. _TelosRX is LegitScript-certified. Compounded medications are not FDA-approved and are prepared under federal compounding regulations. Approval is subject to evaluation by a licensed provider; approval is not guaranteed. Individual results vary. TelosRX operates as an online-first, asynchronous telehealth service._ Start your private evaluation at [TelosRX](https://telosrx.com). **Tags:** comparison, GLP-1, retatrutide, tirzepatide, triple agonist, weight loss --- > Source: [Telos RX](https://www.telosrx.com/blogs/glp1/retatrutide-vs-tirzepatide-triple-vs-dual-agonist)